Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874501 | 0.84 | ADORA1 (0.40) | ADORA1ADORA2BADORA2AADORA3MEN1 | |
| SCHEMBL875339 | 0.82 | ADORA1 (0.40) | ADORA1ADORA2BADORA2AADORA3MEN1 | |
| SCHEMBL3114286 | 0.81 | ADORA1 (0.48) | ADORA1ADORA2BADORA2AADORA3MEN1 | |
| SCHEMBL3119933 | 0.80 | ADORA1 (0.49) | ADORA1ADORA2BADORA2AADORA3MEN1 | |
| SCHEMBL3111626 | 0.80 | ADORA1 (0.49) | ADORA1ADORA2BADORA2AADORA3MEN1 | |
| SCHEMBL13268091 | 0.79 | ADORA1 (0.39) | ADORA1ADORA2BADORA2AADORA3MEN1 | |
| SCHEMBL836659 | 0.77 | ADORA2B (0.42) | ADORA1ADORA2BADORA2AADORA3 | |
| SCHEMBL3114995 | 0.77 | ADORA1 (0.44) | ADORA1ADORA2BADORA2AADORA3MEN1 | |
| SCHEMBL838390 | 0.76 | ADORA2B (0.42) | ADORA1ADORA2BADORA2AADORA3 | |
| SCHEMBL838163 | 0.76 | ADORA2B (0.56) | ADORA1ADORA2BADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143264-B2 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, XDH, GPR88 | ADORA1 29/4885ADORA2B 94/4885ADORA2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.